BioCentury
ARTICLE | Clinical News

Apatorsen: Phase II ongoing

December 21, 2015 8:00 AM UTC

OncoGenex said an independent DSMB recommended continuation of the investigator-led, open-label, U.S. Phase II Borealis-2 trial comparing 600 mg IV apatorsen on days 1, 8 and 15 plus IV docetaxel on d...